New insight on a possible mechanism of progestogens in terms of breast cancer risk

Hormone Molecular Biology and Clinical Investigation

Volumn 6, Issue 1, 2011, Pages 185-192

  Neubauer, Hans ^a   Chen, Rong ^b   Schneck, Helen ^a   Knorrp, Thomas ^c   Templin, Markus F ^c   Fehm, Tanja ^a   Cahill, Michael A ^a,d   Seeger, Harald ^a   Yu, Qi ^b   Mueck, Alfred O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d CHARLES STURT UNIVERSITY   (Australia)

Author keywords

progesterone receptor membrane component 1; progestogens; proliferation; signal cascade

Indexed keywords

EID: 85012188705     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.082     Document Type: Article

References (44)

1. Crudden G., Loesel R., Craven RJ. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol 2005;26:142-6.
2. Neubauer H., Clare SE., Wozny W., Schwall GP., Poznanovic S., Stegmann W., Vogel U., Sotlar K., Wallwiener D., Kurek R., Fehm T., Cahill MA. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphoryla-tion of PGRMC1. Breast Cancer Res 2008;10:R85.
3. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105: 16-36.
4. Rohe HJ., Ahmed IS., Twist KE., Craven RL. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling., P450 activation and drug binding. Pharmacol Ther 2009;121:14-9.
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. J Am Med Assoc 2002;288:321-33.
6. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004;291:1701-1712.
7. Stefanick ML., Anderson GL., Margolis KL., Hendrix SL., Roda-bough RJ., Paskett ED., Lane DS., Hubbell FA., Assaf AR., Sarto GE., Schenken RS., Yasmeen S., Lessin L., Chlebowski RT., WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. J Am Med Assoc 2006;295:1647-57.
8. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-11.
9. Schoonen WG., Joosten JW., Kloosterboer HJ. Effects of two classes of progestins., pregnane and 19-nortestosterone derivatives., on cell growth of human breast tumor cells: 1. MCF-7 cell lines. J. Steroid Biochem Mol Biol 1995;55:423-37.
10. Cappelletti V., Miodini P., Fioravanti L., DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995;15:2551-6.
11. Kramer EA., Seeger H., Kramer B., Wallwiener D., Mueck AO. The effect of progesterone., testosterone and synthetic proges-togens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006; 27:139-41.
12. Catherino WH., Jeng MH., Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945-52.
13. Franke HR., Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003;46(Suppl 1):S55-8.
14. Meyer C., Schmid R., Scriba PC., Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996;239: 726-33.
15. Munton RP., Tweedie-Cullen R., Livingstone-Zatchej M., Wei-nandy F., Waidelich M., Longo D., Gehrig P., Potthast F., Rutis-hauser D., Gerrits B., Panse C., Schlapbach R., Mansuy IM. Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 2007;6:283-93.
16. Ahmed IS., Rohe HJ., Twist KE., Craven RJ. PGRMC1 (progesterone receptor membrane component 1) associates with EGFR and regulates erlotinib sensitivity. Biol Chem 2010;285: 24775-82.
17. Neubauer H., Adam G., Seeger H., Mueck AO., Solomayer E., Wallwiener D., Cahill MA., Fehm T. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;3:230-9.
18. Min L., Strushkevich NV., Harnastai IN., Iwamoto H., Gilep AA., Takemori H., Usanov SA., Nonaka Y., Hori H., Vinson GP., Oka-moto M. Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J 2005;272:5832-43.
19. Nolte I., Jeckel D., Wieland FT., Sohn K. Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim Biophys Acta 2000;1543:123-30.
20. Peluso JJ., Liu X., Saunders MM., Claffey KP., Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cis-platin by progesterone receptor membrane component-1. J Clin Endocrinol Metab 2008;93:1592-9.
21. Peluso JJ., Romak J., Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's anti-apoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008;149:534-43.
22. Peluso JJ., Pappalardo A., Losel R., Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 2006;147:3133-40.
23. Swiatek-De Lange M., Stampfl A., Hauck SM., Zischka H., Gloeckner CJ., Deeg CA., Ueffing M. Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells. Glia 2007;55:1061-73.
24. Pirnia F., Pawlak M., Thallinger GG., Gierke B., Templin MF., Kappeler A., Betticher DC., Gloor B., Borner MM. Novel functional profiling approach combining reverse phase protein microarrays and human 3-D ex vivo tissue cultures: expression of apoptosis-related proteins in human colon cancer. Proteomics 2009;9:3535-48.
25. Martinez S., Pasten P., Suarez K., Garcia A., Nualart F., Montecino M., Hinrichs MV., Olate J. Classical Xenopus laevis progesterone receptor associates to the plasma membrane through its ligand-binding domain. J Cell Physiol 2007;211:560-7.
26. Peluso JJ., Liu X., Gawkowska A., Lodde V., Wu CA. Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. Mol Cell Endocrinol 2010;320:153-61.
27. Svensson LO., Johnson SH., Olsson SE. Plasma concentrations of medroxyprogesterone acetate., estradiol and estrone following oral administration of Klimaxil., Trisequence/Provera, and Divi-na, a randomised., single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994;18:229-38.
28. Stanczyk FZ., Brenner PF., Mishell DR., Ortiz A., Gentzschein EK., Goebelsmann U. A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978;18:615-33.
29. Fernandes MS., Brosens JJ., Gellersen B. Honey., we need to talk about the membrane progestin receptors. Steroids 2008;73: 942-52.
30. Bagowski CP., Myers JW., Ferrell JE Jr. The classical progesterone receptor associates with p42 MAPK and is involved in phosphatidylinositol 3-kinase signaling in Xenopus oocytes. J Biol Chem 2001;276:37708-14.
31. Mifsud W., Bateman A. Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol 2002;3:RESEARCH0068.
32. Hand RA., Craven RJ. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem 2003;90:534-47.
33. Olsen JV., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Global., in vivo., and site-specific phosphorylation dynamics in signaling networks. Cell 2006;127:635-48.
34. Liu L., Wang J., Zhao L., Nilsen J., McClure K., Wong K., Brinton RD. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology 2009;150:3186-96.
35. Syed V., Ulinski G., Mok SC., Yiu GK., Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
36. Stouffer RL. Progesterone as a mediator of gonadotrophin action in the corpus luteum: beyond steroidogenesis. Hum Reprod Update 2003;9:99-117.
37. Fujii T., Hoover DJ., Channing CP. Changes in inhibin activity., and progesterone., oestrogen and androstenedione concentrations., in rat follicular fluid throughout the oestrous cycle. J Reprod Fertil 1983;69:307-14.
38. Peluso JJ., Fernandez G., Pappalardo A., White B. Membrane-initiated events account for progesterone's ability to regulate intracellular free calcium and inhibit rat granulosa cell mitosis. Biol Reprod 2002;67:379-85.
39. Kuhl H. Pharmakologie von Sexualsteroiden. Gynakologe 1998;31:832-47.
40. Magnusson C., Baron JA., Correia N., Bergstrom R., Adami HO., Persson I. Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
41. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65-73.
42. Kuhnz W., Heuner A., Hiimpel M., Seifert W., Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception 1997;56:379-85.
43. Jeng MH., Parker CJ., Jordan VC. Estrogenic potential of pro-gestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539-56.
44. Sauter ER., Ross E., Daly M., Klein-Szanto A., Engstrom PF., Sorling A., Malick J., Ehya H. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997;76:494-501.